A new a agent (MV140: a sublingual preparation of whole-cell inactivated bacteria) was studied in a controlled trial of modest size and duration, and showed promising clinical efficacy in reducing recurrent UTI in women suffering from this condition.
top of page
General Critical Care
Public·386 members
bottom of page